HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Social Factors Likely Explain Colon Ca Racial Disparities
After controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis.
HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
PFS Improves in BRAF V600E+ CRC With Encorafenib Combo
Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.
Neoadjuvant SCRT Combo May Prolong Survival in Advanced Rectal Cancer
Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
PFS Improves in BRAF V600E+ CRC With Encorafenib Combo
Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.
Neoadjuvant SCRT Combo May Prolong Survival in Advanced Rectal Cancer
Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.